Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Fitch: Debt-Financed M&A Stressing US Pharma Credit Profiles

By Pharmaceutical Processing | December 8, 2014

The debt-financed acquisition of Cubist Pharmaceuticals by Merck for $9.5 billion is the latest in a string of large, debt-financed acquisitions that are stressing the credit profiles of US healthcare companies, according to Fitch Ratings.

Encouraged by accommodative credit market conditions, more companies in the US healthcare sector have recently been willing to sacrifice credit ratings to finance acquisitions. While higher debt levels are a credit concern, the impact on ratings has been defrayed by the strong business rational supporting these transactions.

The Cubist deal is no exception as we believe the acquisition constructive. Cubist’s fairly differentiated medicines will add to Merck’s portfolio of treatments in the acute hospital care segment of the market. At the outset, Cubist’s products will enhance the company’s ability to address gram-positive, gram-negative, and clostridium difficile infections. In addition, Cubist’s Entereg helps to improve recovery times in patients who undergo bowel surgery. In the intermediate term, Cubist’s late-stage pipeline also complements Merck’s acute-care drug development efforts.

On balance, Fitch expects the acquisition will strengthen Merck’s growth opportunities, particularly in non-US/European markets. The transaction should also provide for cost synergies over the longer term. While integration risk is present, Fitch’s main concern relates to the Merck’s capital structure in the intermediate term.

Merck’s ratings remain on Negative Outlook following the announcement of the transaction. The financing of the acquisition will lead to higher leverage, but the ultimate influence on the company’s ratings will depend upon management of the capital structure, particularly regarding any potential redemptions of existing debt, over the next 6-12-month period.

Related Articles Read More >

This is a screenshot from a Varda Space Industries promotional video showing a space capsule with the company's logo docking onto a satellite.
Varda raises $187M Series C for drug manufacturing in space
This is the logo of Hikma.
Hikma to spend another $1B on US manufacturing, R&D
Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE